A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis

Alan K. Matsumoto, Agustin Melian, David R. Mandel, Harris H. McIlwain, David Borenstein, Peng Liang Zhao, Christopher R. Lines, Barry J. Gertz, Sean Curtis

Research output: Contribution to journalArticle

Abstract

Objective. To evaluate the efficacy and tolerability of the highly selective cyclooxygenase-2 (COX-2) inhibitor etoricoxib for the treatment of rheumatoid arthritis (RA). Methods. A double blind, randomized, placebo and active comparator controlled, 12 week study conducted at 88 US sites. Eligible patients were chronic nonsteroidal antiinflammatory drug (NSAID) users with clinical worsening of RA upon withdrawal of prestudy NSAID. Patients received either placebo, etoricoxib 90 mg once daily, or naproxen 500 mg twice daily (2:2:1 allocation ratio). Primary efficacy measures: patient and investigator global assessments of disease activity and direct assessment of arthritis by counts of tender and swollen joints. Key secondary measures: patient global assessment of pain, the Stanford Health Assessment Questionnaire, and the percentage of patients both completing the study and meeting the ACR20 criteria. Tolerability was assessed by tabulation of adverse events and routine laboratory evaluations. Results. In all, 816 patients were randomized (placebo = 323, etoricoxib = 323, naproxen = 170), and 448 completed 12 weeks of treatment (placebo = 122, etoricoxib = 230, naproxen = 96). Compared with patients receiving placebo, patients receiving etoricoxib and naproxen showed significant improvements in all efficacy endpoints (p <0.01). Compared with patients receiving naproxen, patients receiving etoricoxib demonstrated significant improvements (p <0.05) on all primary endpoints and most other endpoints including ACR20 criteria. The percentage of patients who achieved an ACR20 response and who completed the study was 21%, 53%, and 39% in the placebo, etoricoxib and naproxen groups, respectively. Etoricoxib and naproxen were both generally well tolerated. Conclusion. In this study, etoricoxib 90 mg once daily was more effective than either placebo or naproxen 500 mg twice daily for treating patients with RA over 12 weeks. Etoricoxib 90 mg was generally well tolerated in patients with RA.

Original languageEnglish (US)
Pages (from-to)1623-1630
Number of pages8
JournalJournal of Rheumatology
Volume29
Issue number8
StatePublished - 2002
Externally publishedYes

Fingerprint

etoricoxib
Rheumatoid Arthritis
Randomized Controlled Trials
Naproxen
Placebos
Therapeutics
Anti-Inflammatory Agents

Keywords

  • COX-2 inhibitors
  • Etoricoxib
  • Naproxen
  • Nonsteroidal antiinflammatory drugs
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Matsumoto, A. K., Melian, A., Mandel, D. R., McIlwain, H. H., Borenstein, D., Zhao, P. L., ... Curtis, S. (2002). A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. Journal of Rheumatology, 29(8), 1623-1630.

A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. / Matsumoto, Alan K.; Melian, Agustin; Mandel, David R.; McIlwain, Harris H.; Borenstein, David; Zhao, Peng Liang; Lines, Christopher R.; Gertz, Barry J.; Curtis, Sean.

In: Journal of Rheumatology, Vol. 29, No. 8, 2002, p. 1623-1630.

Research output: Contribution to journalArticle

Matsumoto, AK, Melian, A, Mandel, DR, McIlwain, HH, Borenstein, D, Zhao, PL, Lines, CR, Gertz, BJ & Curtis, S 2002, 'A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis', Journal of Rheumatology, vol. 29, no. 8, pp. 1623-1630.
Matsumoto AK, Melian A, Mandel DR, McIlwain HH, Borenstein D, Zhao PL et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. Journal of Rheumatology. 2002;29(8):1623-1630.
Matsumoto, Alan K. ; Melian, Agustin ; Mandel, David R. ; McIlwain, Harris H. ; Borenstein, David ; Zhao, Peng Liang ; Lines, Christopher R. ; Gertz, Barry J. ; Curtis, Sean. / A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. In: Journal of Rheumatology. 2002 ; Vol. 29, No. 8. pp. 1623-1630.
@article{0d5b5488b5ad40ec831c42c3b74866c4,
title = "A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis",
abstract = "Objective. To evaluate the efficacy and tolerability of the highly selective cyclooxygenase-2 (COX-2) inhibitor etoricoxib for the treatment of rheumatoid arthritis (RA). Methods. A double blind, randomized, placebo and active comparator controlled, 12 week study conducted at 88 US sites. Eligible patients were chronic nonsteroidal antiinflammatory drug (NSAID) users with clinical worsening of RA upon withdrawal of prestudy NSAID. Patients received either placebo, etoricoxib 90 mg once daily, or naproxen 500 mg twice daily (2:2:1 allocation ratio). Primary efficacy measures: patient and investigator global assessments of disease activity and direct assessment of arthritis by counts of tender and swollen joints. Key secondary measures: patient global assessment of pain, the Stanford Health Assessment Questionnaire, and the percentage of patients both completing the study and meeting the ACR20 criteria. Tolerability was assessed by tabulation of adverse events and routine laboratory evaluations. Results. In all, 816 patients were randomized (placebo = 323, etoricoxib = 323, naproxen = 170), and 448 completed 12 weeks of treatment (placebo = 122, etoricoxib = 230, naproxen = 96). Compared with patients receiving placebo, patients receiving etoricoxib and naproxen showed significant improvements in all efficacy endpoints (p <0.01). Compared with patients receiving naproxen, patients receiving etoricoxib demonstrated significant improvements (p <0.05) on all primary endpoints and most other endpoints including ACR20 criteria. The percentage of patients who achieved an ACR20 response and who completed the study was 21{\%}, 53{\%}, and 39{\%} in the placebo, etoricoxib and naproxen groups, respectively. Etoricoxib and naproxen were both generally well tolerated. Conclusion. In this study, etoricoxib 90 mg once daily was more effective than either placebo or naproxen 500 mg twice daily for treating patients with RA over 12 weeks. Etoricoxib 90 mg was generally well tolerated in patients with RA.",
keywords = "COX-2 inhibitors, Etoricoxib, Naproxen, Nonsteroidal antiinflammatory drugs, Rheumatoid arthritis",
author = "Matsumoto, {Alan K.} and Agustin Melian and Mandel, {David R.} and McIlwain, {Harris H.} and David Borenstein and Zhao, {Peng Liang} and Lines, {Christopher R.} and Gertz, {Barry J.} and Sean Curtis",
year = "2002",
language = "English (US)",
volume = "29",
pages = "1623--1630",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "8",

}

TY - JOUR

T1 - A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis

AU - Matsumoto, Alan K.

AU - Melian, Agustin

AU - Mandel, David R.

AU - McIlwain, Harris H.

AU - Borenstein, David

AU - Zhao, Peng Liang

AU - Lines, Christopher R.

AU - Gertz, Barry J.

AU - Curtis, Sean

PY - 2002

Y1 - 2002

N2 - Objective. To evaluate the efficacy and tolerability of the highly selective cyclooxygenase-2 (COX-2) inhibitor etoricoxib for the treatment of rheumatoid arthritis (RA). Methods. A double blind, randomized, placebo and active comparator controlled, 12 week study conducted at 88 US sites. Eligible patients were chronic nonsteroidal antiinflammatory drug (NSAID) users with clinical worsening of RA upon withdrawal of prestudy NSAID. Patients received either placebo, etoricoxib 90 mg once daily, or naproxen 500 mg twice daily (2:2:1 allocation ratio). Primary efficacy measures: patient and investigator global assessments of disease activity and direct assessment of arthritis by counts of tender and swollen joints. Key secondary measures: patient global assessment of pain, the Stanford Health Assessment Questionnaire, and the percentage of patients both completing the study and meeting the ACR20 criteria. Tolerability was assessed by tabulation of adverse events and routine laboratory evaluations. Results. In all, 816 patients were randomized (placebo = 323, etoricoxib = 323, naproxen = 170), and 448 completed 12 weeks of treatment (placebo = 122, etoricoxib = 230, naproxen = 96). Compared with patients receiving placebo, patients receiving etoricoxib and naproxen showed significant improvements in all efficacy endpoints (p <0.01). Compared with patients receiving naproxen, patients receiving etoricoxib demonstrated significant improvements (p <0.05) on all primary endpoints and most other endpoints including ACR20 criteria. The percentage of patients who achieved an ACR20 response and who completed the study was 21%, 53%, and 39% in the placebo, etoricoxib and naproxen groups, respectively. Etoricoxib and naproxen were both generally well tolerated. Conclusion. In this study, etoricoxib 90 mg once daily was more effective than either placebo or naproxen 500 mg twice daily for treating patients with RA over 12 weeks. Etoricoxib 90 mg was generally well tolerated in patients with RA.

AB - Objective. To evaluate the efficacy and tolerability of the highly selective cyclooxygenase-2 (COX-2) inhibitor etoricoxib for the treatment of rheumatoid arthritis (RA). Methods. A double blind, randomized, placebo and active comparator controlled, 12 week study conducted at 88 US sites. Eligible patients were chronic nonsteroidal antiinflammatory drug (NSAID) users with clinical worsening of RA upon withdrawal of prestudy NSAID. Patients received either placebo, etoricoxib 90 mg once daily, or naproxen 500 mg twice daily (2:2:1 allocation ratio). Primary efficacy measures: patient and investigator global assessments of disease activity and direct assessment of arthritis by counts of tender and swollen joints. Key secondary measures: patient global assessment of pain, the Stanford Health Assessment Questionnaire, and the percentage of patients both completing the study and meeting the ACR20 criteria. Tolerability was assessed by tabulation of adverse events and routine laboratory evaluations. Results. In all, 816 patients were randomized (placebo = 323, etoricoxib = 323, naproxen = 170), and 448 completed 12 weeks of treatment (placebo = 122, etoricoxib = 230, naproxen = 96). Compared with patients receiving placebo, patients receiving etoricoxib and naproxen showed significant improvements in all efficacy endpoints (p <0.01). Compared with patients receiving naproxen, patients receiving etoricoxib demonstrated significant improvements (p <0.05) on all primary endpoints and most other endpoints including ACR20 criteria. The percentage of patients who achieved an ACR20 response and who completed the study was 21%, 53%, and 39% in the placebo, etoricoxib and naproxen groups, respectively. Etoricoxib and naproxen were both generally well tolerated. Conclusion. In this study, etoricoxib 90 mg once daily was more effective than either placebo or naproxen 500 mg twice daily for treating patients with RA over 12 weeks. Etoricoxib 90 mg was generally well tolerated in patients with RA.

KW - COX-2 inhibitors

KW - Etoricoxib

KW - Naproxen

KW - Nonsteroidal antiinflammatory drugs

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=0036021129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036021129&partnerID=8YFLogxK

M3 - Article

C2 - 12180720

AN - SCOPUS:0036021129

VL - 29

SP - 1623

EP - 1630

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 8

ER -